Dr. Karen Harris -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Karen Harris, a Internal Medicine physician based in City, LA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Karen Harris has received $565.16 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Karen Harris
- Medical Specialty: Internal Medicine
- Practice Location: City, LA, Louisiana
- NPI Number: 1238139543
- Transparency Score: 50/100
- Payment Records Span: 2024-05-29 to 2024-05-29
Payment Summary
Dr. Karen Harris has received a total of $565.16 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $565.16 per transaction.
- Total Payments Received: $565.16
- Number of Transactions: 1
- Average Payment: $565.16
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
Payment Breakdown by Category
The following table shows how Dr. Karen Harris's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|
The largest payment category for Dr. Karen Harris is Speaking & Education, accounting for 0% ($0.00) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Karen Harris. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Pfizer Inc | $565.16 | 1 |
Dr. Karen Harris has a financial relationship with Pfizer Inc, receiving $565.16 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Karen Harris's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Karen Harris has received $565.16 across 1 pharmaceutical payments as a Internal Medicine physician in City, LA. Top paying companies include Pfizer Inc ($565.16). Dr. Karen Harris received a single payment of $565 from Pfizer Inc. in 2024. The payment is categorized as general and represents 100% of her total pharmaceutical payments.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Karen Harris is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Consumers should be aware that Dr. Karen Harris has received a single payment from Pfizer Inc., which is the only pharmaceutical company involved in her payments. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Karen Harris Compares to Other Internal Medicine Physicians
Compared to peers in Internal Medicine, Dr. Karen Harris has a lower level of pharmaceutical industry interaction.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Karen Harris in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Pfizer Inc | $565.16 | general | N/A | 2024-05-29 | Not Assessed |
Frequently Asked Questions About Dr. Karen Harris's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Karen Harris received?
Karen Harris has received a total of $565.16 across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Karen Harris taking too much pharma money?
Karen Harris has received $565.16 in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Internal Medicine), the types of payments, and how they compare to peers. The largest payment category is general ($565.16). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Karen Harris?
The top pharmaceutical companies paying Karen Harris are: Pfizer Inc ($565.16). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Karen Harris receive?
Karen Harris's payments by type: general: $565.16.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Karen Harris's payments compare to other Internal Medicine doctors?
To compare, look at the total amount ($565.16), number of payments (1), and the types of payments received. Internal Medicine physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Karen Harris's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1238139543). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Karen Harris's pharma payment profile?
Single payment from a single company, indicating high concentration. Karen Harris has received $565.16 in total pharma payments.
How does Karen Harris compare to peers in Internal Medicine?
Compared to peers in Internal Medicine, Dr. Karen Harris has a lower level of pharmaceutical industry interaction.
Are Karen Harris's pharma relationships typical for Internal Medicine?
Payment type is general, which is the only type of payment listed.
What should patients of Karen Harris know about these payments?
Consumers should be aware that Dr. Karen Harris has received a single payment from Pfizer Inc., which is the only pharmaceutical company involved in her payments.
What patterns are visible in Karen Harris's payment history?
No trend data available beyond the single year provided.
Understanding This Doctor Payment Report
This transparency report for Dr. Karen Harris is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Karen Harris's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Karen Harris and all other physicians can be accessed at the official CMS Open Payments website.
Other Internal Medicine Physicians
Compare Dr. Karen Harris's pharmaceutical payments with other Internal Medicine physicians ranked by total pharma payments received.
| Physician | State | Total Payments |
|---|---|---|
| Karen Harris | AL | $373,560.30 |
| Andrew Young | MN | $373,004.12 |
| Catherine Morris | MI | $329,087.36 |
| Benjamin Cook | AL | $290,577.64 |
| Patricia Davis | IN | $229,890.74 |
| Karen Harris | PA | $223,458.75 |
| Charles Baker | OH | $174,454.86 |
| Amanda Lewis | TN | $161,516.05 |
| Amanda Lewis | AL | $145,697.34 |
| Christine Edwards | TX | $144,283.94 |
Top Doctors in Louisiana
These physicians in Louisiana have received the highest pharmaceutical payments. See how Dr. Karen Harris compares to peers in the same state.
| Physician | Specialty | Total Payments |
|---|---|---|
| Stephanie King | Neurology | $308,624.53 |
| Timothy Rogers | Dermatology | $300,324.91 |
| Charles Baker | Cardiology | $189,146.74 |
| Amanda Lewis | Psychiatry | $186,870.46 |
| Jeffrey Campbell | Neurology | $174,169.56 |
| Brian Wright | Oncology | $163,512.80 |
| Laura Hall | Hematology | $146,752.97 |
| Michelle Scott | Oncology | $135,372.63 |
| David Kim | Oncology | $132,860.92 |
| David Kim | Genetics | $130,702.83 |
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- Louisiana Physician Payments -- Browse pharmaceutical payments to physicians in Louisiana
- Internal Medicine Physicians in Louisiana -- Compare Dr. Karen Harris to peers in the same state and specialty
- Pfizer Inc Payment Profile -- View all payments made by Dr. Karen Harris's largest pharmaceutical partner
- Pfizer Inc Payments to Internal Medicine Doctors
- All Medical Specialties -- Browse pharma payments organized by specialty
- All States -- Browse pharma payments organized by state
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Karen Harris's NPI (1238139543) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.